Fig. 1From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2Histograms showing the age distribution for vaccination frequency and vaccination uptake for both Pfizer-BioNTech and Oxford-AstraZeneca vaccines on and before 24 May 2021 constructed using CIPHA dataBack to article page